A multiplexed real-time PCR assay for simultaneous quantification of human immunodeficiency virus and Hepatitis B virus for low-and-middle- income countries.

A multiplexed real-time PCR assay for simultaneous quantification of human immunodeficiency virus and Hepatitis B virus for low-and-middle- income countries.

Publication date: Dec 01, 2024

Due to shared routes of transmission, including sexual contact and vertical transmission, HIV-HBV co-infection is common, particularly in sub-Saharan Africa. Measurement of viral load (VL), for both HIV and HBV, plays a critical role for determining their infectious phase and monitoring response to antiviral therapy. Implementation of viral load testing in clinical settings is a significant challenge in resource-limited countries, notably because of cost and availability issues. We designed HIV and HBV primers for conserved regions of the HIV and HBV genomes that were specifically adapted to viral strains circulating in West Africa that are HIV-1 subtype CRF02AG and HBV genotype E. We first validated two monoplex qPCR assays for individual quantification and, then developed a multiplex qPCR for simultaneous quantification of both viruses. HIV RNA and HBV DNA amplification was performed in a single tube using a one-step reverse transcription-PCR reaction with primers and probes targeting both viruses. Performance characteristics such as the quantification range, sensitivity, and specificity of this multiplex qPCR assay were compared to reference qPCR tests for both HIV and HBV viral load quantification. The multiplex assay was validated using clinical samples from co- or mono-infected patients and gave comparable viral load quantification to the HIV and HBV reference test respectively. The multiplex qPCR demonstrated an overall sensitivity of 71. 25 % [68. 16-74. 3] for HBV and 82 % [78. 09-85. 90] for HIV and an overall specificity of 100 % [94. 95-100] for both viruses. Although the overall sensitivities of the HIV and HBV assays were lower than the commercial comparator assays, the sensitivity in the clinical decision range of >1000 copies/mL for HIV was 80 % [71. 26-88. 73] and >1000 IU/mL for HBV was 100 % [95. 51-100] which indicates the test results can be used to guide treatment decisions. This in-house developed multiplex qPCR assay represents a useful diagnostic tool as it can be performed on affordable “open” real-time PCR platforms currently used for HIV or SARS-Cov-2 infection surveillance in Mali.

Concepts Keywords
Affordable Coinfection
Hiv Developing Countries
Pcr DNA Primers
Therapy DNA Primers
DNA, Viral
DNA, Viral
HBV DNA
Hepatitis B
Hepatitis B virus
Hepatitis B virus
HIV Infections
HIV-1
Humans
Real-time PCR
RNA, Viral
RNA, Viral
Sensitivity and Specificity
Viral Load
Viral load

Semantics

Type Source Name
disease IDO assay
disease IDO immunodeficiency
disease MESH co-infection
disease MESH viral load
disease IDO role
disease MESH SARS-Cov-2 infection
pathway REACTOME SARS-CoV-2 Infection
disease MESH Hepatitis B
pathway KEGG Hepatitis B
disease MESH HIV Infections

Original Article

(Visited 1 times, 1 visits today)